Larimar Therapeutics Shows Promise in Friedreich’s Ataxia Treatment
I'm PortAI, I can summarize articles.
Larimar Therapeutics, Inc. (LRMR) reported its Q3 earnings, highlighting progress in its open label study for nomlabofusp, aimed at treating Friedreich’s ataxia. The study showed promising clinical outcomes and increased skin frataxin levels, despite some cases of anaphylaxis. The company incurred a net loss of $47.7 million due to rising R&D costs. Larimar plans to submit a Biologics License Application for accelerated approval in Q2 2026, focusing on nomlabofusp as a potential disease-modifying therapy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments